

SNBL's Subsidiary, SNLD, Announces Posters to be Presented at the Upcoming International Congress of Parkinson's Disease and Movement Disorders®

TOKYO and KAGOSHIMA, Japan, October 6, 2025 – Shin Nippon Biomedical Laboratories, Ltd. (TSE Prime: 2395, hereinafter “SNBL”) announces that SNLD, Ltd. (hereinafter “SNLD”), a consolidated subsidiary of SNBL specialized in development of novel therapies for the treatment of Parkinson's Disease (hereinafter “PD”) utilizing SNBL's nasal drug delivery platform technology, will present two posters at the International Congress of Parkinson's Disease and Movement Disorders®. The meeting will be held from October 5 to 9, 2025, in Honolulu, Hawaii, United States.

TR-012001 is being developed as a novel on-demand therapy candidate to treat OFF episodes in PD. The presentations will highlight the results of Phase I Study and Phase II proof-of-concept clinical study of TR-012001, a nasal levodopa. The Phase I study was conducted to evaluate the safety, tolerability, and pharmacokinetics of levodopa in Japanese healthy subjects (N=21). The Phase II study was conducted in Japanese PD patients (N=12). The results of Phase I and Phase II study were first presented at the 66th Annual Meeting of the Japanese Society of Neurology (2025) and the American Academy of Neurology Annual Meeting, 2025, respectively.

Presentation Details:

Title: A Phase I Study of TR-012001, a Nasal Levodopa, in Healthy Adult Japanese Male Subjects

Poster Number/Category: 877/Parkinson's Disease: Clinical Trials

Date/Time: Tuesday, October 7, 2025: from 12:00 noon to 2:30 p.m. (HST).

Author: Ryota Ise (SNLD, Ltd., Tokyo, Japan), et al.

Title: A Proof-of-Concept Study of TR-012001, a Nasal Levodopa, in Patients with Parkinson's Disease with OFF Episodes, Without Dopa Decarboxylase Inhibitor.

Poster Number/Category: 889/Parkinson's Disease: Clinical Trials

Date/Time: Tuesday, October 7, 2025: from 12:00 noon to 2:30 p.m. (HST).

Author: Masahiro Nomoto (Clinical Research Center and Neurology, Saiseikai Imabari Hospital, Imabari, Japan), et al.

About Parkinson's Disease (PD)

A progressive, neurodegenerative disorder first described in 1817 by Dr. James Parkinson in the UK, that affects predominantly the dopamine-producing neurons in a specific area of the brain called substantia nigra. It is known for four major symptoms: tremor (shaking in the arms and legs), rigidity (muscle and joint stiffness), bradykinesia (slowing down of movement), and postural instability (impaired balance and falls). In addition to these characteristic symptoms, non-motor symptoms such as psychiatric and cognitive problems are also gaining increasing attention in recent years. The estimated number of PD patients in Japan is about 250,000, while the number in the U.S. is about 1 million. The number of PD patients is expected to increase as the population ages.



About OFF episodes

OFF episodes are return of PD symptoms, resulted from shorten and unstable levodopa therapeutic effect after long-term levodopa treatment, and are not easy to manage, affecting patient's quality of life (QOL).

About Levodopa

Levodopa is a dopamine precursor capable of crossing the blood-brain barrier, converts to dopamine in the brain, and exhibits antiparkinsonian effects. It has been the primary treatment for PD for many decades.

About SNLD

SNLD is a wholly-owned subsidiary of SNBL established in October 2020 for the purpose of clinical development of novel intranasal therapies for PD and other central nervous system diseases. For more information, please visit [SNLD website \(Japanese only\)](#).

Inquiries

Shin Nippon Biomedical Laboratories, Ltd.

IR & Corporate Communications

Email: ir@snbl.com

#####